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Post-remission therapy of patients with acute myeloid
leukemia (AML) is critical for the elimination of mini-
mal residual disease (MRD) and a prerequisite for
achieving cure. Cellular immunotherapy is a highly
effective treatment option as demonstrated by the low
relapse rate after allogeneic stem cell transplantation
(SCT). However, many patients are not eligible for this
treatment. Therapeutic vaccination with autologous den-
dritic cells (DCs) is a promising strategy to induce
anti-cancer immune responses. We have developed a
GMP-compliant protocol for the generation of next-gen-
eration DCs. A short 3-day differentiation period is com-
bined with a novel maturation cocktail including a TLR7/
8 agonist, resulting in DCs characterized by a positive
co-stimulatory profile, high production of IL-12p70,
polarization of T helper cells into Th1 and efficient sti-
mulation of cytotoxic T lymphocytes and NK cells.
In a current proof-of-concept Phase I/II clinical trial we
evaluate next-generation DCs as post-remission therapy
for AML patients with a non-favorable risk profile
(NCT01734304). Standard exclusion criteria apply, and
patients have to be ineligible for allogeneic SCT. DCs are
generated from patients´ monocytes and loaded with
RNA encoding the leukemia-associated antigens WT1,
PRAME or CMVpp65 as an adjuvant and surrogate anti-
gen. Patients are vaccinated intradermally with 5x106
DCs of each of the three different batches up to 10 times
within 26 weeks. Primary endpoints are feasibility and
safety, and secondary endpoints include immune
responses and disease control with a particular focus on
MRD conversion. Phase I will include 6 patients and
Phase II another 14 patients.
So far, three patients have been enrolled and two of
them have been vaccinated for at least six times each.
DCs fulfilled all quality criteria (phenotype, viability,
sterility, cell count, purity), and after thawing main-
tained their positive co-stimulatory profile as well as
their capacity to secrete high amounts of IL-12p70. DCs
expressed all three antigens and were able to induce a
selective T cell response in vitro, suggesting proper anti-
gen processing and presentation. In both vaccinated
patients delayed type hypersensitivity reactions devel-
oped. Apart from erythema and itching at the injection
site, no higher grade adverse events have been observed.
As of yet, both patients are relapse-free and MRD-nega-
tive. Up-to-date clinical and immunomonitoring data
including evaluation of T and NK cell activation and
specific T cell responses will be presented.
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